Notification system for Advance Care Planning

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Advance Care Planning
Notification system - Other
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will study how well hospitals do at caring for seriously ill patients when they are notified of the patient's condition.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 6 Secondary · Reporting Duration: Up to 6 months

Up to 30 days
Number of advance care planning codes billed as measured by electronic health record data
Number of advance care planning notes as measured by electronic health record data
Number of advance care planning paperwork filed as measured by electronic health record data
Number of patients discharged to hospice as measured by electronic health record data
Number of patients' code status changed to Do-Not-Resuscitate as measured by electronic health record data
Up to 6 months
Number of patient deaths as measured by electronic health record data
Number of patient re-admitted to the hospital as measured by electronic health record data
Up to 90 days
Number of Palliative Care Consults (Inpatient/Outpatient) as measured by electronic health record data

Trial Safety

Trial Design

2 Treatment Groups

Control
1 of 2
Intervention
1 of 2
Active Control
Experimental Treatment

100 Total Participants · 2 Treatment Groups

Primary Treatment: Notification system · No Placebo Group · N/A

Intervention
Other
Experimental Group · 1 Intervention: Notification system · Intervention Types: Other
ControlNoIntervention Group · 1 Intervention: Control · Intervention Types:

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 6 months

Who is running the clinical trial?

Duke UniversityLead Sponsor
2,154 Previous Clinical Trials
3,179,713 Total Patients Enrolled
2 Trials studying Advance Care Planning
889 Patients Enrolled for Advance Care Planning
David Casarett, MDPrincipal InvestigatorDuke University
Jessica Ma, MDPrincipal InvestigatorDuke University

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are at least 18 years old.\n

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 3rd, 2021

Last Reviewed: October 2nd, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.